Blood
Hydroxyurea (hydroxycarbamide)
A ribonucleotide reductase inhibitor that raises fetal haemoglobin in sickle cell anaemia, reducing painful crises, acute chest syndrome and transfusions.
Mécanisme d’action
- Hydroxyurea inhibits ribonucleotide reductase, which makes the deoxyribonucleotides needed for DNA.
- Under this stress, red cell precursors switch on fetal haemoglobin (HbF) production.
- HbF does not polymerise with HbS, so cells sickle less; fewer neutrophils and less adhesion also help.
Cibles moléculaires
- Ribonucleotide reductase: Inhibitor
Médicaments : Hydroxyurea (hydroxycarbamide)
- Hydroxyurea (By mouth.)
Indications thérapeutiques
- Sickle cell anaemia: fewer painful crises and episodes of acute chest syndrome
- Myeloproliferative disorders such as polycythaemia vera and chronic myeloid leukaemia
Maladies traitées
Effets indésirables
- Bone marrow suppression, so blood counts are monitored
- Skin and nail darkening
- Gastrointestinal upset
Contre-indications selon le terrain
- Pregnancy (Contre-indiqué): It inhibits DNA synthesis and is teratogenic.
- Severe bone marrow suppression (Contre-indiqué): It suppresses the marrow further.
Rédigé d’après
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 42, Drugs for Anemia, Drugs used to treat sickle cell disease
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 33, Agents Used in Cytopenias; Hematopoietic Growth Factors, Hydroxyurea in sickle cell disease
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.